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Mutations in the gene encoding myotubularin-related protein 2 (MTMR2) are responsible for autosomal
recessive Charcot–Marie–Tooth disease type 4B1 (CMT4B1), a severe hereditary motor and sensory
neuropathy characterized by focally folded myelin sheaths and demyelination. MTMR2 belongs to the
myotubularin family, which is characterized by the presence of a phosphatase domain. Myotubularin (MTM),
the archetype member of this family, is mutated in X-linked myotubular myopathy. Although MTMR2 and MTM
are closely related, they are likely to have different functions. Recent studies revealed that MTM
dephosphorylates speciﬁcally phosphatidylinositol 3-phosphate. Here we analyze the biochemical properties
of the mouse Mtmr2 protein, which shares 97% amino acid identity with human MTMR2. We show that
phosphatidylinositol-3-phosphate is also a substrate for Mtmr2, but, unlike myotubularin, Mtmr2 depho-
sphorylates phosphatidylinositol 3,5-bisphosphate with high efﬁciency and peak activity at neutral pH. We
demonstrate that the known disease-associated MTMR2mutations lead to dramatically reduced phosphatase
activity, suggesting that the MTMR2 phosphatase activity is crucial for the proper function of peripheral
nerves in CMT4B1. Expression analysis of Mtmr2 suggests particularly high levels in neurons. Thus, the
demyelinating neuropathy CMT4B1 might be triggered by the malfunction of neural membrane recycling,
membrane trafﬁcking, and/or endocytic or exocytotic processes, combined with altered axon–Schwann cell
interactions. Furthermore, the different biochemical properties of MTM and MTMR2 offer a potential
explanation for the different human diseases caused by mutations in their respective genes.
INTRODUCTION
Charcot–Marie–Tooth disease type 4B (CMT4B) is an
autosomal recessive demyelinating neuropathy characterized
by focally folded myelin sheaths and demyelination of
peripheral nerves, associated with reduced nerve conduction
velocity. The disease is characterized by onset in early
childhood with symmetrical distal and proximal muscle
weakness. Adult patients are seriously handicapped and
wheelchair-bound (1). Although clinically homogenous, two
different gene loci have been identified for CMT4B (2).
CMT4B1 was mapped to chromosome 11q22 (3), and
myotubularin-related protein 2 (MTMR2) was identified as
the disease-causing gene at this locus (4). To date, about half a
dozen MTMR2 mutations have been identified (4,5).
MTMR2 belongs to the myotubularin family of eukaryotic
phosphatases (6). Myotubularin (MTM), the founder member,
was identified by positional cloning to be mutated in X-linked
myotubular myopathy (XLMTM) (7). XLMTM is characterized
by hypotonia and generalized muscle weakness in newborn
males and death within the first months of life. The muscle
cells of affected patients show large, centrally located nuclei,
which is typical for fetal myotubes, indicating that the muscle
is arrested prior to differentiation of myofiber formation (8).
Myotubularin-related proteins are defined by the presence of
conserved phosphatase and SET (Suvar 3–9, Enhancer of zeste,
Trithorax)-interacting domains (SID) (9,10). Although the
phosphatase domain was initially identified as a protein
tyrosine/dual-specificity phosphatase (PTP/DSP), only minor
phosphatase activity towards phosphorylated proteins has been
observed in vitro (11). The discovery that phosphatase and
tensin homologue (PTEN), a tumor suppressor gene product
with a PTP/DSP domain that is frequently mutated in a variety
of tumors, dephosphorylates phosphatidylinositol 3,4,5-
trisphosphate (12) led to the identification of phosphoinositides
as the major myotubularin substrates. MTM shows specific
activity towards phosphatidylinositol 3-phosphate [PI(3)P], a
metabolite that plays a key role in membrane and vesicular
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trafficking in yeast (13) and mammalian cells (14). Phosphoi-
nositides can be further phosphorylated on multiple sites of the
inositol ring to generate distinct second messengers that are
involved in diverse cellular processes such as cell survival,
proliferation, differentiation and cytoskeleton reorganization
(15). PI(3)P is constitutively synthesized from phosphatidyli-
nositol by a class III phosphatidylinositol 3-kinase (PI3K) (16)
and is specifically located on membranes associated with the
endocytic pathway (17,18). PI(3)P recruits proteins with a
FYVE zinc-finger domain to these membranes (19,20) and can
become phosphorylated by phosphoinositide 5-kinase with a
FYVE domain (PIKfyve), an enzyme that localizes to multi-
vesicular bodies, to form phosphatidylinositol 3,5-bisphosphate
[PI(3,5)P2] (21). This phospolipid is involved in the response to
cellular stress (22) and the recycling of membrane from
vacuoles/lysosomes (23), and regulates sorting of membrane
protein cargo into the vacuole via endosomal multivesicular
bodies (24).
To understand the molecular mechanisms underlying the
human diseases caused by mutations in the MTM and MTMR2
genes, it is crucial to characterize the biochemical properties of
the encoded proteins. In the current study, we show that MTM
and Mtmr2 (the mouse orthologue of MTMR2) have distinct
biochemical properties. Whereas MTM dephosphorylates
mainly PI(3)P (11), Mtmr2 is able to dephosphorylate PI(3)P
and PI(3,5)P2 efficiently. In addition, the two phosphatases
exhibit different pH optima. These results indicate that MTM
and Mtmr2 fulfill partially different functions, possibly at
different locations within the cell. This is in line with the
observation that the two proteins cannot compensate for each
other in the disease situation. Mutations in MTMR2 that cause
CMT4B1, assayed in the mutated products of the mouse
orthologue Mtmr2, lead to drastically reduced enzymatic
activity, suggesting a link between the disease and phosphatase
activity. CMT4B1 is clinically characterized by demyelination
and focally folded myelin sheaths, pointing to a primary defect
in the Schwann cell. However, Mtmr2 is highly expressed by
motor and sensory neurons, indicating an important contribu-
tion of axon–Schwann cell interactions to the disease
phenotype (25).
RESULTS
Sequence of Mtmr2 cDNA
Mtmr2 cDNA was obtained by RT–PCR from both mouse
brain and sciatic nerve RNA and matched the sequences of the
available expressed sequence tag (EST) clones. The cDNA
codes for a protein of 643 amino acids that shares 97% identity
with the human orthologue (4). Most of the divergent residues
are localized towards the N terminus, whereas the known
structural motifs – the GRAM (glucosyltransferase, Rab-like
GTPase activator and myotubularin), phosphatase, SID, PDZ
(PSD95/Dlg/ZO-1)-binding motifs – are almost completely
conserved (6,10,26,27). In addition, the same amino acid
residues that are mutated in the characterized CMT4B1 patients
are also found in the mouse protein (Fig. 1A). The nearest
family members in the mouse, Mtm and Mtmr1, share 63% and
68% identity respectively, with Mtmr2 (Fig. 1B).
The genomic structure of the mouse Mtmr2 gene was
determined using publicly available genomic sequences and
verified by sequencing the exon/intron boundaries on a
bacterial artificial chromosome (BAC) clone containing the
Mtmr2 gene (S. Bonneick et al., in preparation). The locations
of all exon/intron junctions are identical between the human
MTMR1 and MTMR2 genes and the mouse Mtmr2 gene
(Fig. 1C, Table 1), except for the untranslated exon 15, which is
split into exon 15 and exon 16 in MTMR1 (4,28). We also
identified an additional exon between exon 2 and exon 3 by
RT–PCR (data not shown) and screening of the EST database
(termed exon 2a). Because this exon is only rarely used in
mouse (data not shown) and contains two inframe stop codons,
the corresponding cDNA was not analyzed further.
Catalytic properties of Mtmr2
Myotubularins were initially identified as members of the PTP/
DSP family. However, recent studies have shown that
phosphoinositides are the main substrates of this family
(11,29). Previous experiments revealed that PI(3)P is a
substrate for MTM (11,29), and PI(3,5)P2 has been reported
to be a substrate for MTMR3 (30). To determine the substrate
specificity of Mtmr2, we expressed Mtmr2 protein in
Escherichia coli as a fusion protein with N-terminal glutathione
S-transferase (GST) and C-terminal His(6) tags and measured
the phosphatase activity of the resulting fusion protein with
different phosphatidylinositol phosphates as substrates in a
malachite green-based assay (31). Strong catalytic activity was
detected with two of the seven substrates tested. This activity
was highest with PI(3,5)P2, and PI(3)P was dephosphorylated
at an approximately 4-fold lower rate (Fig. 2A). Mtmr2 showed
only minimal dephosphorylation of PI(4)P, PI(5)P, PI(3,4)P2,
PI(4,5)P2 and PI(3,4,5)P3. To identify which phosphate group
was released by Mtmr2 from PI(3,5)P2, two different assays
were carried out. Using substrates fluorescently labeled on the
fatty acid chain, we show that PI(3,5)P2 is converted to PI(5)P
and not to phosphatidylinositol, demonstrating that only a
single phosphate was removed. In the same assay, Mtmr2
dephosphorylated PI(3)P to phosphatidylinositol, but PI(5)P
was not dephosphorylated (Fig. 2B). When phosphatidylino-
sitol, PI(4)P and PI(5)P were radioactively labeled at position
D3 with PI3K, Mtmr2 was able to remove the radioactivity
from PI(3)P and PI(3,5)P2, indicating that the phosphate at
position D3 is removed (Fig. 2C). PI(3,5)P2 was not completely
dephosphorylated at D3 in this assay, although it was incubated
with an excess of enzyme – possibly because the specific
conditions in the PI3K-coupled assay were not optimal.
PI(3,4)P2 was not a substrate, confirming the results from the
malachite green-based assay. We conclude that PI(3)P and, in
particular, PI(3,5)P2 are the main substrates for Mtmr2, which
selectively removes the phosphate at position D3, but not at
position D5.
We also determined the influence of the pH on the catalytic
activity of Mtmr2 to obtain some indirect insights about its
subcellular localization. The phosphatase activity was highest
between pH 7.0 and 7.5, and was strongly reduced at pH 6.5
and below. These results did not depend on the substrate, since
PI(3)P and PI(3,5)P2 showed the same pH dependence (Fig. 3).
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Figure 1. Characterization of the Mtmr2 gene. (A) Alignment of the mouse Mtmr2 amino acid sequence with the corresponding human MTMR2 sequence. Dif-
ferences are marked in bold, known mutations in human patients are boxed and the characterized structural motifs are shaded. (B) Degree of amino acid identity
within the myotubularin family given in percentages. (C) Genomic organization of the mouse Mtmr2 gene. Exon 2a is an alternatively spliced exon containing two
stop codons. Black boxes are translated regions and white boxes are untranslated regions. Intron sizes are not drawn to scale.
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Influence of CMT4B1-associated mutations on the function
of MTMR2
To understand the molecular basis of CMT4B1, we studied the
effects of disease-associated mutations on phosphatase activity.
MTM mutations have been shown to result in loss of catalytic
activity, but the tested mutations were all localized in or nearby
the phosphatase domain (11). Three described MTMR2
mutations directly affect the phosphatase domain (E276X,
Q426X and Q482X), and it might have been anticipated that
they have lost their catalytic activities (Fig. 4A). Interestingly,
the CMT4B1-associated deletion of amino acids phenylalanine
494 to glutamate 531, which corresponds to a skipping of exon
13 (coding for part of the SID domain adjacent to the
phosphatase domain; Fig. 1A), as well as a stop mutation at
tyrosine 579, also led to a complete loss of phosphatase
activity. Only the missense mutation G103E, which is located
approximately 150 amino acids N-terminal to the phosphatase
domain, retained marginal catalytic activity (Fig. 4A). Loss of
catalytic activity was observed with both substrates, PI(3,5)P2
and PI(3)P, on all mutants mentioned above. This effect appears
to be specific for the disease-associated forms, because other,
artificially designed, Mtmr2 mutations in the phosphatase
domain (K333T and R443E) or the deletion of the PDZ-
binding motif (T641X) did not cause loss of phosphatase
activity (data not shown).
Expression of MTMR2 in the nervous system
Since mutations in the human MTMR2 gene lead to the
demyelinating disease CMT4B1, we analyzed the expression of
this phosphatase in the peripheral nervous system (PNS) of the
mouse. In situ hybridization with an Mtmr2 antisense probe
revealed a strong signal in dorsal root ganglia (DRG) (Fig. 5A)
and in motor neurons (Fig. 6F). No signal was obtained with
the corresponding Mtmr2 sense probe (Fig. 5B). Surprisingly,
no discernible staining was observed in the peripheral nerve,
possibly because of limited sensitivity of the assay, since RT–
PCR analyses of sciatic nerve tissue revealed detectable Mtmr2
mRNA (data not shown). To examine whether the strong
staining observed by in situ hybridization analysis of DRG was
due to neuronal or glial Mtmr2 expression, we performed
double immunostainings on dissociated DRG cultures with
anti-Mtmr2 antibodies and the glial marker Sox10 (32)
(Fig. 5C). Sensory neurons (as judged by morphology in
Fig. 5C and double staining with anti-neurofilament antibodies;
data not shown) display high expression of Mtmr2 mainly in
the cell soma and neurites. In contrast, Mtmr2 immunoreactiv-
ity was not detected in Sox10-positive satellite glial cells
(Fig. 5C). Neuronal expression of Mtmr2 was also found in the
central nervous system (CNS) (Fig. 6). Mtmr2 transcripts were
detected in the mitral cells of the olfactory bulbs (Fig. 6A), in
distinct thalamic nuclei and in nuclei of the globus pallidus
(Fig. 6B), in all CA fields of the hippocampus and in the
dentate gyrus (Fig. 6C), in Purkinje cells of the cerebellum
(Fig. 6D), and in the deep cerebellar nuclei (Fig. 6E). In the
pons, expression was found in the vestibular nuclei, the spinal
trigeminal nuclei and the facial nuclei (Fig. 6E).
Since ubiquitous expression of MTMR2 has been reported
based on northern blot analysis of human tissue (6) and
because of the early onset of CMT4B1, we examined Mtmr2
expression in mouse embryos. Widespread expression was
observed at embryonal day 16.5, with particularly high levels in
the forebrain, DRG, the facial and trigeminal ganglia, kidney,
adrenal gland, and lung (Fig. 7).
DISCUSSION
Mutations in the human MTMR2 gene are responsible for
CMT4B1, a severe autosomal recessive peripheral neuropathy.
MTMR2 is highly conserved in many species and there are at
least eight related proteins in human and mice (6).
Interestingly, mutations in one of the closest MTMR2
homologues, MTM, cause the severe disorder X-linked
myotubular myopathy. Hence, although these proteins are
highly similar and have in part overlapping expression
patterns (6), they are not completely redundant. In order to
understand the molecular basis of these distinct effects, we
have analysed the enzymatic properties of Mtmr2 and
Table 1. Exon/intron organization of the Mtmr2 gene
Acceptor site Exon number (size) Donor site
Exon 1 (>120 bp) CACTGTCCAG gtgaggccgggcg
ttgtcttttgtag TGCTTCTACT Exon 2 (106 bp) TGACTTGAGG gtatgtatattgc
aaatccctcacag GAGTGCCCAG Exon 2a (105 bp) AATTCTATAG gtaagtcacataa
tatccccatgcag GTCCTGAGGG Exon 3 (76 bp) AAAGATATGG gtctgtaatgttt
tttgtcgtttcag CCAAAGATGT Exon 4 (95 bp) CATGGAGCGG gtgaggcttcttg
tttcatcttgcag GACCCCCCAT Exon 5 (111 bp) TGTGTGCAAG gtaaattttacaa
atatcttttctag GATATCAGGA Exon 6 (102 bp) TAATGGCTTG gtaaatgtttctc
gtttattttgtag CCTCTTTTTG Exon 7 (84 bp) CAGAAGGCAG gtacgtgcttttc
atgtcatgtgtag GGAATTCCAA Exon 8 (150 bp) CCGGATCCCA gtaagtaggctga
tcctttcatgaag GTTTTATCCT Exon 9 (189 bp) TGCCAATAAG gtaaggtgttctt
ccctcttttgcag GCAAAGGGGG Exon 10 (186 bp) ACACATTAAG gtgtgtatttact
aacttgttttcag CTCATTCTTG Exon 11 (207 bp) ATTCCAACTA gtgagtaaagaac
gtctttgcttcag AGAGTTGGCC Exon 12 (93 bp) GACAAGACAG gtaagacgtcatc
gctcaatttgcag TTCCCTACCG Exon 13 (114 bp) GGGGAAAGAG gtaaagtatgatc
ttccctcttgcag AATCTTCCTA Exon 14 (177 bp) GAAACCTCAG gtacatatctgta
tttgctcttgcag GAACCTATCC Exon 15 (>1050 bp)
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compared them with the available data on other proteins of
the myotubularin family.
Recombinant Mtmr2 was expressed in E. coli as a fusion
protein and its phosphatase activity towards different phos-
phoinositides was measured. Mtmr2 dephosphorylates
PI(3,5)P2 and PI(3)P with high efficiency and shows only
marginal activity towards the other substrates tested. Kim et al.
(33) showed also in a very recent report that MTMR2 is able to
dephosphorylate PI(3)P, but did not detect activity towards
PI(3,5)P2. We have tested PI(3,5)P2 from two different suppliers
in the malachite green-based assay and have reproducibly
observed PI(3,5)P2 dephosphorylation. Equal substrate speci-
ficity was observed when substrates containing a fluorescent
label on the fatty acid chain were used and with substrates that
were labelled enzymatically to incorporate [32P]phosphate at
the D3 position of phosphoinositides using recombinant PI3Kg.
Based on these data, we conclude that Mtmr2 dephosphorylates
also PI(3,5)P2 at its D3 position to produce PI(5)P.
Figure 2. Substrate specificity of Mtmr2. (A) Mtmr2 dephosphorylates mainly PI(3,5)P2 and PI(3)P in a malachite green-based assay. The other five substrates
tested were dephosphorylated with much reduced activity. The lipid carrier in this reaction, phosphatidylserine (PS), was tested separately as a negative control.
Enzyme-specific activity is expressed as moles of phosphate released per minute per mole of enzyme (mean SD, n¼ 3). (B) Di-C6-NBD6-phosphoinositide sub-
strates were incubated with wild-type Mtmr2, mutant Mtmr2 C417S (inactivated phosphatase domain) and without enzyme. Wild-type Mtmr2 dephosphorylated
PI(3,5)P2 to PI(5)P and PI(3)P to phosphatidylinositol (PI). (C) Dephosphorylation of substrates labeled with [
32P]phosphate at position D3. PI(3,5)P2 and PI(3)P
lose radioactivity after treatment with an excess of Mtmr2, indicating that Mtmr2 acts at position D3. PI(3,4)P2 was not dephosphorylated; see also (A).
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While several studies describe the important and established
function of PI(3)P in endocytosis and vesicular trafficking
(17,18), less is known about the functions of PI(3,5)P2. The
basal level of this lipid is low compared with those of other
phosphatidylinositol phosphates, especially PI(3)P (22).
PI(3,5)P2 levels are, however, transiently increased by external
signals such as hypoosmotic stress (22) or treatment with
ultraviolet light (34). Also, more physiological signals, such as
the stimulation of B and T cells with interleukin-2, lead to an
increase in PI(3,5)P2 (34). Functional approaches in mamma-
lian cells by blocking PI(3,5)P2 production using overexpres-
sion of a kinase-inactive form of PIKfyve caused swollen
vacuoles, indicating that PI(3,5)P2 is important for cell
morphology and membrane homeostasis (35). Similarly,
inactivation of the yeast PIKfyve orthologue Fab1p leads to
vacuolar acidification and increased vacuole size (23). These
and other studies show conclusively that correct regulation of
PI(3,5)P2 levels is crucial for cell morphology, vesicular
trafficking and membrane homeostasis. The function of the
accumulated PI(5)P remains to be elucidated, but recent studies
suggest that it is also involved in the cellular stress response
in plants (36).
MTMR2 is not the only protein of the myotubularin family
that shows this substrate specificity. MTMR3/FYVE-DSP1 also
dephosphorylates PI(3,5)P2 and PI(3)P, but its maximal activity
is at pH 4.5 (30,37). MTMR3 together with MTMR4/FYVE-
DSP2 forms a subgroup in the myotubularin gene family with
a different domain composition. These enzymes contain a
C-terminal FYVE domain, indicating that they are targeted to
PI(3)P-containing membranes. The precise subcellular locali-
zation of MTMR2 is not yet known, but it is likely that it acts in
the cytosol or in non-acidic vesicles, based on its optimal
Figure 3. pH dependence of the catalytic activity. The pH dependence of the phosphatase activity was measured using a malachite green-based assay. The activity
peaked between pH 7.0 and 7.5 and was independent of the substrate used. Enzyme specific activity is expressed as moles of phosphate released per minute per
mole of enzyme (meanSD, n¼ 3).
Figure 4. Enzymatic activities of disease-associated forms. Four of the five disease-associated Mtmr2 proteins tested lose their catalytic activity completely; only
G103E retains some residual activity (the disease-associated frameshift mutation at Y579 was mimicked by a stop mutation). C417S is a negative control with a
mutation of the cysteine in the active site (mean SD; n¼ 3; **, below detection limit).
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activity at neutral pH. Indeed, recent results suggest a cytosolic
and membrane-associated localization of MTMR2 as well as an
ability to relocalize to rac-induced membrane ruffles (38).
Our analysis of CMT4B1-associated MTMR2 mutations
revealed that four of five mutated proteins tested lost their
phosphatase activity completely, and one mutant (Mtmr2
G103E) retained only very low catalytic activity. Although
we cannot exclude other contributing factors, including
altered protein stability and/or mislocalization of the mutant
proteins, these results indicate that CMT4B1 is strongly
correlated with the loss of MTMR2 phosphatase activity, as
described previously for MTM in X-linked myotubular
myopathy (11). Based on our data and the function of the
substrates and products of MTMR2 mentioned above, a
defect in membrane homeostasis and vesicular transport of
lipids and/or proteins related to altered phosphatidylinositol
metabolism and potentially cellular stress might be the
crucial element in the molecular basis of CMT4B1. Such a
disease mechanism would be in line with the special
metabolic requirements of Schwann cells, in that they might
be particularly vulnerable to such imbalances during
myelination, when huge amounts of lipids and proteins have
to be synthesized and accurately trafficked within a short
period of time. The deleterious problem could be either due
to a more systemic effect, or altered trafficking of specific
myelin components might cause CMT4B1 indirectly. In
agreement with such a hypothesis, CMT4B1 has been
clinically classified as a demyelinating neuropathy. To date,
all forms of demyelinating neuropathies have been associated
with genetic defects leading to aberrant Schwann cell
function (recently reviewed in 25). Interestingly and
surprisingly, our expression analysis suggests that Mtmr2 is
mainly expressed in the adult by neurons. In the PNS, we
observed strong expression in the DRG, while no signal was
detectable in Schwann cells. To confirm this result, we
examined the Mtmr2 mRNA level in the DRG in
comparison to the sciatic nerve by quantitative RT–PCR.
Indeed, higher levels were found in the DRG (data not
shown). Nevertheless, low levels of Mtmr2 mRNA were also
present in the adult sciatic nerve, and this expression may be
important for the formation and stability of the myelin
sheath. However, given the intimate communication between
Schwann cells and neurons in peripheral nerves, a primary
neuronal phenotype, possibly due to defects in neuronal
vesicle trafficking and/or endocytosis, is not inconceivable,
followed by secondary demyelination (25). Alternatively, the
CMT4B1 disease mechanism might involve both neurons
and glial cells. Tissue-specific gene ablation techniques will
be required to determine the contributions of the individual
cell types.
Mtmr2 expression is not restricted to the PNS, since we
observed neuronal expression in various areas of the CNS.
Interestingly, CMT4B1 patients do not show a CNS phenotype,
although the pronounced cranial nerve involvement in the
disease might be related to the strong expression of Mtmr2 in
brain stem nuclei.
In summary, we provide evidence that MTMR2 and MTM
have distinct biochemical properties that may help to explain the
different human diseases associated with mutated forms of these
proteins and the lack of redundancy despite overlapping
expression patterns. Additional factors may also contribute,
including other substrates yet to be discovered, or other domains
Figure 5. Expression of Mtmr2 in the murine DRG and sciatic nerve. (A) Mtmr2 expression revealed by in situ hybridization in the DRG of mice at postnatal day 6.
(B) Hybridization with the sense probe showed no signal. (C) Immunostaining of dissociated DRG cultures. Morphologically identifiable neurons were Mtmr2
positive. The Mtmr2 (red) staining does not co-localize with the glial marker Sox10 (green). (D) Phase picture. Bar in (B) for (A) and (B) equals 50mm; bar
in (D) for (C) and (D) equals 20mm.
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of these proteins that might be necessary to give the proteins a
restricted subcellular localization thereby restricting them to
specific functions. A detailed analysis of the members of this
intriguing family of phosphatases, including determining their
cellular expression levels, precise subcellular localization, and
the identification of potentially associated proteins in different
physiological conditions of neurons and glial cells, will be
required to elucidate the molecular basis of CMT4B1.
Figure 6. Expression of Mtmr2 in the adult mouse CNS. Expression was found in (A) the mitral cell layer (arrow) of the olfactory bulbs, (B) the cerebral cortex
(double arrow), the anteriodorsal (arrow) and reticular (open arrow) thalamic nuclei, as well as nuclei of the globus pallidus (arrowhead), (C) the CA1, CA2 and
CA3 regions of the hippocampus and the dentate gyrus (dg), (D) the Purkinje cells (arrow), and (E) the lateral nuclei of the cerebellum (double arrow), the ves-
tibular nuclei (arrow), the spinal trigeminal nuclei (open arrow) and the facial nuclei (arrowhead) of the pons. (F) Expression in the spinal cord is detected mainly in
the ventral horn in morphologically identifiable motorneurons (arrow). Bars in (A)–(C) and (E) are 500mm; bar in (D) is 100mm, and bar in (F) is 250mm.
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MATERIALS AND METHODS
Isolation of mouse Mtmr2 cDNA
The Mtmr2 cDNA was obtained by RT–PCR using RNA from
adult mouse brain and sciatic nerve as template. Three
different, overlapping fragments were generated with primers
based on known EST sequences. Fragment 1 containing the
first 678 bp of the coding region was amplified with the primers
MTMR2-for1 (50-GCA KCG GCC TCC AGT TTC TC-30) and
pho-back (50-TGC CTT CTG TAC TCT AGA AGG-30),
fragment 2 containing the following 940 bp with the primers
pho2-for (50-AAT GGG TGG AAA CTG TAT GAC C-30) and
pho5-back (50-ATA ACC AGC TGT ACA AGT GGT CC-30),
and fragment 3 with the remaining 478 bp of the coding region
and 887 bp of the 30-untranslated region with the primers pho4-
for (50-GGC AAA TGA CAA GAC AGT TCC-30) and pho6-
back (50-TTG TTA CAG TAC ATT ACA TAT GG-30). For each
fragment, two clones from independent RT–PCR reactions
were sequenced. The full-length Mtmr2 cDNA was then
obtained by fusing these fragments using the BamHI site on
fragments 1 and 2 and the EcoRI site on fragments 2 and 3.
Constructs for expression in E. coli
Recombinant Mtmr2 protein for biochemical analysis was
produced in E. coli as a fusion protein with N-terminal
glutathione S-transferase (GST) and C-terminal His(6) tags. A
BamHI site adjacent to the start ATG of the Mtmr2 cDNA and
the C-terminal His(6) tag with an EcoRI site were introduced
with a PCR-based strategy using the primers GST-MTMR2-for
(50-CGT AGT GGA TCC ATG GAG AAG AGC TCC AGC
TG-30) and MTMR2-Hisback (50-AAC AAC GAA TTC TCA
ATG GTG ATG GTG ATG GTG TAC AAC AGT TTG GAC-
30). The resulting cDNA was cloned into the BamHI/EcoRI-cut
pGEX-2T vector (Pharmacia). The resulting vector pGEX–
Mtmr2 was used for the expression of wild-type protein and as
the starting point for the expression constructs of the mutated
forms of Mtmr2. The following primers were used for
mutagenesis: E276X (50-GAT CGA ATT CTC AGT GAT
GGT GAT GGT GAT GAA GAT GAA TCC AGG A-30),
Q426X (50-GAT CGA ATT CTC AGT GAT GGT GAT GGT
GAT GAG CTG TGC GAT CCC A-30), Q482X (50-GAT CGA
ATT CTC AGT GAT GGT GAT GGT GAT GAA GGA AAA
CAG GTG A-30), Y579X (50-GAT CGA ATT CTC AGT GAT
GGT GAT GGT GAT GTC CCA CCC AGA GCT C-30),
DelEx13a (50-ATT GAC TGT GTC TGG CAA ATG ACA
AGA CAG AAT CTT CCT AAG AAG-30), DelEx13b (50-GAC
AGG TCA CCT GTT TTC CTT CAG TTT ATT GAC TGT
GTC TGG-30), G103E (50-GAC TTA CAT ATG TCC ATT
CAC TGG TGC TGT GCG AGA AAC GCT GAC TGT C-30),
PDZ-Del (50-GAT CGA ATT CTC AGT GAT GGT GAT GGT
GAT GTT GGA CAG GAG TCA C-30) and C417S (50-GGG
AAG ACG TCT GTG GTG GTA CAC TCC AGT GAT GGA
TGG-30).
Protein expression and purification
For protein expression, 1 l of LB/ampicillin medium was
inoculated with a 50 ml overnight culture of E. coli BL21
(DE3) cells (Stratagene) transformed with the pGEX–Mtmr2
expression plasmids constructed as described above. The
bacteria were shaken for 4 h at room temperature, induced
with 0.8 mM isopropyl-b-D-thiogalactopyranoside (IPTG), and
then further incubated for 16 h at room temperature. After
centrifugation, the cells were lysed by sonification in lysis
buffer (20 mM Tris–HCl, 300 mM NaCl, 10 mM imidazole, 1%
Triton X-100, 20 mM b-mercaptoethanol and 1 mM PMSF,
pH 8.0). The lysate was then centrifuged for 30 min at
13 000 r.p.m. in a SS34 rotor, and supernatant containing the
soluble protein was loaded on Ni-NTA agarose beads (Qiagen).
The beads were washed twice with washing buffer (20 mM
Tris–HCl, 300 mM NaCl and 20 mM imidazole, pH 8.0) and
then eluted with elution buffer (20 mM Tris–HCl, 300 mM NaCl
and 250 mM imidazole, pH 8.0). The eluate was loaded on GST-
Sepharose (Pharmacia), washed once with washing buffer, and
then eluted with 10 mM reduced glutathione in 50 mM Tris–HCl
(pH 8.0). The concentration of the protein was determined by
SDS–PAGE with bovine serum albumin (BSA) as standard.
Glycerol was added to a final concentration of 30%, and the
protein was stored at 20C.
Figure 7. In situ hybridization on a sagital section of an E16.5 mouse embryo.
Mtmr2 expression is prominent in the forebrain (fb), trigeminal ganglion (tg),
facial ganglion (fg), submandibular gland (sg), lung (lu), adrenal gland (ag),
kidney (ki) and dorsal root ganglia (drg). Bar equals 1 mm.
Human Molecular Genetics, 2002, Vol. 11, No. 13 1577
Phosphoinositide phosphatase assay
Phosphoinositides were obtained from the following sources:
PI(3)P, PI(4)P, PI(4,5)P2, PI(3,4)P2 and PI(3,4,5)P3 from
Calbiochem, PI(5)P from Echelon, and PI(3,5)P2 from
Calbiochem and Echelon. The lipids were dissolved in
chloroform/methanol/water (50 : 50 : 15 v/v) and the appro-
priate amounts were deposited in a 1.5 ml reaction tube. The
organic solvent was removed under reduced pressure before the
aqueous reaction buffer was added, and a lipid suspension was
formed by sonication. Assays were performed at 37C in a
buffer consisting of 50 mM sodium acetate, 25 mM BisTris,
25 mM Tris, 2 mM DTT, 5% glycerol, 50 mM phosphoinositide
phosphate and 0.5 mM phosphatidylserine at the indicated pH.
The reaction was started by the addition of recombinant
protein, and 10 ml aliquots were removed at different time
points (0.5–20 min). The reaction was stopped by adding 15 ml
of 10 mM N-ethylmaleimide to the reaction mixture and
incubating at 95C for 10 min, followed by centrifugation at
18 000 g for 15 min at 4C. Phosphate release was measured
with a malachite green-based assay as described before (31).
The detection limit was 10 pmol released phosphate. Phospha-
tase assays with phosphorylated di-C6-NBD6 phosphatidyli-
nositols (Echelon) were performed as described before (39)
using 1 mg lipid in 100 ml assay buffer (50 mM ammonium
carbonate, pH 7.0, 2 mM DTT and 1 mg enzyme). Phosphoinosi-
tides were separated on oxalate-coated (1.2% potassium oxalate
in methanol/water 2 : 3, v/v) silicagel 60W plates (Merck), with
c h l o r o f o r m / a c e t o n e / m e t h a n o l / a c e t i c a c i d / wa t e r
(80 : 30 : 26 : 24 : 14 v/v) as mobile phase (40). For the PI3K/
Mtmr2 coupled assay, phosphoinositide substrates [phosphati-
dylinositol (Sigma), PI(4)P (Sigma) and PI(5)P, 5 mg each] were
dissolved separately in chloroform/methanol (2 : 1 v/v) and
mixed with an equal amount of phosphatidylserine. The
nitrogen-dried mixture was sonicated in 40 ml of PI3K reaction
buffer (20 mM HEPES at pH 7.4 and 5 mM MgCl2) and
supplemented with 1 mg of recombinant GST–PI3Kg fusion
protein (41) in 10 ml reaction buffer. The phosphorylation
reaction was started with 15 mCi of [32P]gATP (from ICN) in
10 ml reaction buffer to give a final concentration of 15 mM ATP.
After 20 min at 37C, the temperature was increased to 37C,
and recombinant wild-type or catalytically inactive Mtmr2
protein (1 mg/sample) were added for 20 min. Subsequently,
lipids were extracted after the addition of 100 ml 1 M HCl and
200 ml chloroform/methanol (1 : 1 v/v) as described in (40). The
lipids were separated as described above, and the radioactivity
was quantified by phosphorimaging on a GS-525 from Bio-
Rad.
In situ hybridization
Brain, spinal cord, dorsal root ganglia and sciatic nerve from
adult C57/Bl6 mice were isolated and frozen in OTC
(TissueTec) on dry ice. Twenty-micrometer frozen sections
were mounted on Superfrost slides (Mettler) and air-dried.
Digoxigenin-labeled RNA probes for in situ hybridization were
produced with the full-length cDNA according to the
manufacturer’s recommendation (Roche Diagnostics, Man-
nheim). Hybridization was performed overnight at 72C in
buffer containing 50% formamide, and bound probe was
detected using an anti-DIG-AP antibody (Roche Diagnostics,
Mannheim). As a control, the in situ hybridization was repeated
with a mouse Mtmr2 probe containing only the 30-untranslated
region. The same expression pattern as with the Mtmr2 cDNA
full-length probe was found. Controls with the sense probes
were always performed in parallel, with no appreciable signals
detected.
Immunocytochemistry
A rabbit polyclonal antibody against Mtmr2 was raised using a
recombinant Mtmr2 protein with an N-terminal His tag. Dorsal
root ganglia (DRG) were isolated from C57/Bl6 mice at
postnatal day 6, dissociated by incubation in 0.35 mg/ml
collagenase type I/0.25% trypsin for 40 min at 37C, and plated
on fibronectin-coated 35 mm cell culture dishes. The cells were
cultivated in DMEM/10% FCS for 36 h and then fixed in PBS
containing 3.5% formaldehyde for 10 min at room temperature.
The cells were then permeabilized for 10 min at room
temperature in 0.2% Triton X-100/ 5% normal goat serum
(NGS) in PBS. Mtmr2 labeling was performed using a rabbit
polyclonal antibody diluted 1 : 1000 in 0.2% Triton X-100/ 5%
NGS/PBS. Mouse monoclonal anti-Sox10 antibody (kindly
provided by Dr M. Wegner, University of Erlangen, Germany)
was used in a 1 : 3 dilution. Detection was carried out with
either Cy3-conjugated goat anti-rabbit (Jackson ImmunoRe-
search Laboratories, 1 : 500) or FITC-conjugated goat anti-
mouse IgGs (Sigma, 1 : 300).
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